Atrophic Rhinitis (Bordetella + Pasteurella)

Atrophic rhinitis vaccines provide essential protection against progressive atrophic rhinitis, a significant upper respiratory disease of swine caused by the combined pathogenic actions of Bordetella bronchiseptica and toxigenic strains of Pasteurella multocida. This disease results in degeneration and atrophy of the nasal turbinate bones, causing snout deviation, decreased growth performance, and increased susceptibility to secondary respiratory infections. The economic impact of atrophic rhinitis extends beyond the visibly affected animals to include subclinical growth depression across entire production groups and increased condemnation rates at slaughter.

The pathogenesis of progressive atrophic rhinitis involves a synergistic interaction between the two bacterial species. Bordetella bronchiseptica colonizes the nasal epithelium and creates conditions favorable for secondary infection with toxigenic Pasteurella multocida. The dermonecrotic toxin produced by toxigenic Pasteurella multocida strains is directly responsible for the bone resorption that leads to turbinate atrophy. Vaccines targeting both organisms and neutralizing the Pasteurella multocida toxin provide the most comprehensive protection against disease development.

Modern atrophic rhinitis vaccines typically contain inactivated Bordetella bronchiseptica bacterin components combined with Pasteurella multocida toxoid to stimulate neutralizing antibodies against the dermonecrotic toxin. This combination approach addresses both the predisposing infection and the primary causative agent of bone damage. Some products may additionally include other Pasteurella multocida antigens or adjuvants selected to enhance mucosal immunity in the upper respiratory tract where these organisms establish infection.

Vaccination programs for atrophic rhinitis typically focus on breeding herd immunization to provide passive protection to piglets through colostral antibody transfer. The critical window for turbinate damage occurs during the first weeks of life when the nasal structures are most susceptible to toxin-mediated injury. Maternal antibodies present in colostrum provide protection during this vulnerable period before piglets can mount their own active immune responses. This strategic approach has proven highly effective in reducing the incidence and severity of progressive atrophic rhinitis in commercial swine operations.

The primary indication for atrophic rhinitis vaccine is prevention of progressive atrophic rhinitis in swine herds where Bordetella bronchiseptica and toxigenic Pasteurella multocida are present or pose introduction risk. Herds with history of snout deviation, turbinate damage at slaughter inspection, or documented isolation of these pathogens are strong candidates for vaccination programs. Even herds without overt clinical disease may benefit from vaccination if slaughter plant feedback indicates subclinical turbinate pathology suggestive of atrophic rhinitis activity.

Breeding herd vaccination represents the cornerstone application for atrophic rhinitis vaccines. Gilts entering the breeding herd receive primary vaccination series to establish immunity before their first farrowing, ensuring adequate colostral antibody production for their initial litters. Sows receive booster vaccinations during subsequent gestations, typically administered during late pregnancy to maximize colostral antibody levels at farrowing. This maternal immunization strategy provides passive protection to piglets during the critical early life period.

Protection of piglets from birth through the vulnerable first weeks of life constitutes the ultimate objective of breeding herd vaccination programs. Turbinate bone development is most active during early life, and damage during this period results in permanent structural abnormalities that cannot be reversed by later intervention. Colostral antibodies passively transferred from vaccinated dams provide immediate protection against toxin-mediated injury during this susceptible window, before piglets can develop their own active immunity.

Growth performance improvement represents an important economic indication for atrophic rhinitis vaccination beyond prevention of visible snout deformation. Subclinical turbinate atrophy impairs airflow dynamics and reduces air warming and humidification capacity of the nasal passages, predisposing to lower respiratory infections and reducing feed efficiency. Herds implementing effective vaccination programs commonly observe improvements in average daily gain and feed conversion even when severe clinical disease was not previously apparent.

Reduction of secondary respiratory disease susceptibility provides additional value from atrophic rhinitis control. Damaged nasal passages provide reduced defense against respiratory pathogens that would normally be filtered, warmed, and humidified during nasal breathing. Pigs with turbinate atrophy demonstrate increased susceptibility to pneumonia and other lower respiratory conditions, compounding the direct effects of the primary disease. Vaccination thus contributes to overall respiratory health beyond specific protection against atrophic rhinitis.

Breeding herd vaccination protocols typically involve a two-dose primary series for gilts, with the first dose administered approximately six weeks before breeding and the second dose two to four weeks later. This timing allows full development of immunity before the first pregnancy and ensures maximum antibody production capacity during late gestation when colostrum is being formed. The specific interval between doses follows manufacturer recommendations and may vary between products.

Sow vaccination schedules typically include booster doses administered during late gestation, commonly at two to four weeks before expected farrowing. This timing positions the immune stimulus to enhance colostral antibody concentrations at the time of piglet birth and first suckling. Some programs include mid-gestation boosters for sows with particularly long intervals since previous vaccination, though single late-gestation doses are often sufficient for sows with established immunity from previous vaccination series.

Intramuscular injection in the neck muscles represents the standard administration route for atrophic rhinitis vaccines. The injection site should be selected to allow monitoring for local reactions while avoiding valuable carcass areas. Needle selection appropriate to animal size ensures proper intramuscular delivery without excessive tissue trauma. For breeding females, consistent use of alternating sides of the neck for sequential vaccinations helps distribute any injection site effects and simplifies reaction monitoring.

Proper vaccine handling before and during administration supports optimal product performance. Vaccines should be thoroughly mixed by shaking before use to ensure uniform distribution of antigens and adjuvants that may have settled during storage. Product should be brought to room temperature before injection to improve tolerance and reduce injection site reactions. During vaccination sessions, product should be protected from temperature extremes and direct sunlight.

Dose volumes follow manufacturer specifications, typically two milliliters for most atrophic rhinitis vaccine products. Accurate dosing requires properly calibrated delivery equipment with regular verification. Multidose syringes should be checked at the beginning of vaccination sessions and periodically during use. Precise dosing ensures each animal receives the intended antigen quantity for optimal immune response.

Withdrawal periods for atrophic rhinitis vaccines are generally not specified or are minimal, as inactivated vaccines do not create drug residue concerns. However, breeding animals are typically vaccinated well before any potential slaughter, making withdrawal considerations academic for most practical purposes. Records of vaccination should be maintained as part of comprehensive herd health documentation and food safety programs.

Injection site reactions including transient swelling and discomfort are the most commonly observed side effects of atrophic rhinitis vaccination. These local reactions typically appear within twenty-four to forty-eight hours post-vaccination and resolve spontaneously over one to two weeks without treatment. The intensity of injection site reactions varies between products and individual animals, with adjuvanted vaccines generally producing more pronounced local effects than non-adjuvanted formulations. Proper injection technique minimizes reaction severity.

Systemic reactions including mild fever, temporary inappetence, and reduced activity may occur following vaccination, particularly after the primary vaccination series. These signs reflect normal immune system activation in response to vaccine antigens and typically resolve within twenty-four to seventy-two hours. Most vaccinated animals do not demonstrate obvious systemic effects, and those that do rarely require supportive treatment. Monitoring vaccinated animals allows identification of any individuals requiring attention.

Reproductive impacts represent a theoretical concern when vaccinating pregnant sows, though properly formulated and administered vaccines have not demonstrated significant adverse effects on reproductive performance in field use or controlled studies. The stress associated with vaccination handling may pose greater reproductive risk than the vaccine itself in some circumstances. Vaccination during the most stress-sensitive periods of early pregnancy can be avoided through appropriate scheduling when practical.

Anaphylactic reactions are rare but represent the most serious potential adverse effect of any vaccine administration. Immediate hypersensitivity responses can cause acute respiratory distress and cardiovascular collapse requiring emergency treatment. Epinephrine should be available during all vaccination sessions for treatment of anaphylaxis if it occurs. Animals with history of severe reactions to previous doses of the same or similar products should not be revaccinated without veterinary evaluation and appropriate precautions.

Persistent injection site lesions including sterile abscesses may develop in some animals, particularly following subcutaneous rather than intramuscular injection or when contaminated equipment is used. These lesions may persist for extended periods and require drainage or other treatment if they become problematic. While generally not affecting animal health significantly, they represent departures from optimal vaccine response and emphasize the importance of proper technique.

Clinically ill animals should not receive atrophic rhinitis vaccination until health status has been restored. Systemic illness impairs immune response to vaccination and may increase the likelihood and severity of adverse effects. Sows demonstrating fever, inappetence, respiratory distress, or other signs of active disease should be excluded from vaccination until clinical signs have resolved. Individual animal health assessment should precede vaccination, with questionable animals held for veterinary evaluation.

Previous severe hypersensitivity reaction to the specific vaccine product or its components constitutes an absolute contraindication to repeat vaccination. Animals that have demonstrated anaphylaxis or severe immediate reactions should not receive additional doses of the same product. Alternative products with different formulations may be considered under veterinary guidance, though cross-reactivity between similar vaccines cannot be excluded. Such reactions should be documented in animal health records to prevent inadvertent repeat exposure.

Vaccination during the first several weeks of pregnancy requires consideration of potential reproductive impacts, though atrophic rhinitis vaccines have not demonstrated teratogenic or embryotoxic effects in normal use. The handling stress associated with vaccination may pose greater reproductive risk than the vaccine itself during sensitive early pregnancy. When scheduling permits, positioning vaccination earlier in gilt development or later in gestation reduces theoretical concerns about early pregnancy effects.

Immunosuppressive conditions or medications may impair vaccine response and represent relative contraindications. Animals receiving corticosteroids or other immunosuppressive treatments should have vaccination delayed until an appropriate washout period following treatment discontinuation. Underlying diseases causing immunosuppression warrant veterinary evaluation regarding vaccination timing and expected effectiveness.

Concurrent administration with other inactivated vaccines is common practice and generally does not result in significant immunological interference. Atrophic rhinitis vaccines may be administered on the same day as erysipelas bacterins, parvovirus vaccines, and leptospirosis vaccines that are commonly given to breeding swine during similar production stages. Separate injection sites should be used for each product to allow independent monitoring of injection site reactions and to prevent potential antigen interaction at the injection site.

Modified live virus vaccines present somewhat greater uncertainty regarding potential interactions with inactivated bacterial vaccines. The differing immune activation patterns of live versus killed vaccines may result in some mutual interference when administered simultaneously. Some practitioners prefer separating live and inactivated vaccine administration by one to two weeks when production schedules permit. However, practical constraints often necessitate concurrent administration, which generally produces acceptable immune responses to all products.

Immunosuppressive medications including corticosteroids can significantly reduce antibody response to vaccination. Breeding animals receiving anti-inflammatory or immunosuppressive therapy should ideally complete treatment and experience appropriate drug clearance before vaccination. When treatment and vaccination cannot be separated, reduced vaccine efficacy should be anticipated. Alternative timing or additional doses may be considered under veterinary guidance.

Antimicrobial treatments do not directly affect inactivated vaccine efficacy, as these products do not contain live organisms susceptible to antibiotic effects. However, concurrent antibiotic therapy may complicate interpretation of any post-vaccination clinical signs, as it becomes difficult to distinguish vaccination effects from responses to the antimicrobial treatment or underlying conditions being treated. Documentation of all treatments helps clarify such situations.

Human safety during vaccine handling and administration requires attention to avoid accidental self-injection and minimize exposure to vaccine components. Accidental injection of adjuvanted veterinary vaccines can cause significant local tissue reaction including granuloma formation. Personnel should maintain secure grip on both syringe and animal during injection to prevent erratic animal movement that increases self-injection risk. Used needles should be disposed of immediately into appropriate sharps containers.

Splash exposure to eyes or skin should be addressed through immediate and thorough washing with clean water. While inactivated vaccines do not cause infection, adjuvant and preservative components can cause irritation and allergic reactions in sensitized individuals. Personnel with known allergies to vaccine components should avoid handling these products. Any concerning exposures should be evaluated by a physician with information about the specific vaccine involved.

Vaccine potency depends on proper cold chain maintenance throughout storage and handling. Products should be maintained at two to eight degrees Celsius from manufacture through administration. Freezing damages vaccine integrity and must be avoided. Temperature monitoring during storage and transport provides documentation of appropriate handling. Products exposed to temperatures outside recommended ranges should not be used, as efficacy cannot be assured.

Timely administration of reconstituted products is essential for vaccines requiring preparation before use. Manufacturer specifications for post-reconstitution viability must be followed, with any unused product discarded after the specified interval. Multidose vials should be used within a single day and not stored for future sessions. Appropriate disposal of unused vaccine, containers, and used equipment follows general guidelines for veterinary biological products.

Vaccination represents one component of comprehensive atrophic rhinitis control that should include attention to environmental factors and husbandry practices. Reducing transmission from infected sows to piglets, minimizing stress during the vulnerable early life period, and maintaining good air quality in farrowing facilities all contribute to disease control. Vaccination is most effective when integrated with these management measures rather than relied upon as a standalone intervention.

Refrigerated storage at two to eight degrees Celsius maintains atrophic rhinitis vaccine potency through the manufacturer-specified expiration date. Vaccines should be stored in refrigerators dedicated to or appropriate for veterinary biological products, positioned away from freezer compartments and direct cooling elements. Temperature monitoring through continuous recording devices or at minimum twice-daily manual readings provides documentation of storage conditions and early warning of refrigerator malfunction.

Protection from light supports vaccine stability, as some vaccine components may degrade upon prolonged light exposure. Original cartons and packaging provide appropriate light shielding during storage. During vaccination sessions, products should be protected from direct sunlight and returned to refrigerated storage during extended breaks in vaccination activities. Preparation of only the quantity of vaccine that can be administered within the specified post-opening timeframe reduces waste and ensures potency.

Disposal of unused vaccine, empty containers, and vaccination equipment should follow established protocols for veterinary biological waste. While inactivated products do not pose infectious disease risks, proper disposal ensures environmental responsibility and prevents accidental exposure to vaccine components. Sharp containers should be used for needle disposal, with full containers handled according to local regulations for sharps waste. Empty vaccine bottles should be rinsed before disposal through standard waste streams where permitted.

Commercial maternal line genetics including Yorkshire and Landrace and their crosses demonstrate consistent responses to atrophic rhinitis vaccination without significant breed-specific considerations. These breeds, which form the foundation of most commercial sow herds, have been the primary populations in which vaccines have been developed and tested. Standard vaccination protocols apply across these genetic lines without modification, though individual farm response should be monitored to identify any need for program adjustment.

Terminal sire line genetics including Duroc, Hampshire, and Pietrain typically receive less focus in atrophic rhinitis vaccination programs since these lines rarely enter breeding herds themselves. However, commercial operations using purebred or crossbred finishing pigs from these lines benefit equally from maternal vaccination programs that protect piglets during the vulnerable early life period. The genetics of the sire line do not significantly influence the protection provided by maternal antibodies derived from properly vaccinated dams.

Specialty and heritage breed populations may face different disease challenges than commercial genetics depending on their housing, management, and exposure patterns. Small-scale operations with heritage breeds may have limited atrophic rhinitis experience, making vaccination decisions less straightforward than in commercial herds with documented disease history. Veterinary consultation regarding vaccination needs in these populations should consider the specific epidemiological context.

Showpig populations require attention to vaccination timing relative to exhibition schedules and any health documentation requirements for shows and sales. While atrophic rhinitis vaccination is generally encouraged for all swine populations at risk, specific documentation requirements may influence program design. Breeders maintaining registered stock should ensure vaccination records support any health certification requirements for breeding stock sales.

Other respiratory vaccines commonly included in breeding herd programs alongside atrophic rhinitis immunization include swine influenza virus vaccines, Mycoplasma hyopneumoniae bacterins, and in some regions, Actinobacillus pleuropneumoniae vaccines. These products address different components of the porcine respiratory disease complex and are typically coordinated in comprehensive vaccination programs. Timing considerations may allow some products to be administered on the same day while others may be separated for optimal immune response.

Erysipelas vaccines are frequently administered to breeding swine on similar schedules to atrophic rhinitis vaccines, providing protection against this economically important bacterial disease. Parvovirus vaccines for prevention of reproductive failure represent another common breeding herd vaccine often coordinated with atrophic rhinitis immunization. Leptospirosis vaccines may also be included in combination products or as separate administrations depending on regional disease pressure.

Antimicrobial medications including macrolides, tetracyclines, and potentiated sulfonamides may be used therapeutically to address clinical Bordetella bronchiseptica or Pasteurella multocida infections. However, these treatments cannot reverse turbinate damage once it has occurred and do not replace vaccination for prevention. Antimicrobial treatment is most appropriate for controlling acute disease outbreaks and reducing bacterial shedding, while vaccination provides the foundation for long-term disease control and prevention of the structural damage characteristic of progressive atrophic rhinitis.